3 November 2015 - Janssen-Cilag International NV announced today the submission of a type II variation application to the EMA seeking to broaden the existing marketing authorisation for Imbruvica (ibrutinib) to include previously untreated patients with chronic lymphocytic leukaemia.

For more details, go to: http://www.businesswire.com/news/home/20151103006143/en/Janssen-Submits-Application-EMA-Expand-IMBRUVICA®-ibrutinib